Pfizer Inc. $PFE Shares Sold by Stonehearth Capital Management LLC

Stonehearth Capital Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 8.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,757 shares of the biopharmaceutical company’s stock after selling 1,089 shares during the quarter. Stonehearth Capital Management LLC’s holdings in Pfizer were worth $285,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at $28,000. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 3.8%

Shares of PFE opened at $23.91 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm’s fifty day moving average is $24.79 and its two-hundred day moving average is $24.30. The stock has a market cap of $135.94 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. HSBC dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.